Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.